Susquehanna International Group’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.94M | Sell |
71,241
-120,998
| -63% | -$6.69M | ﹤0.01% | 1533 |
|
|
2025
Q1 | $9.3M | Buy |
192,239
+122,302
| +175% | +$5.91M | ﹤0.01% | 689 |
|
|
2024
Q4 | $2.7M | Buy |
69,937
+29,580
| +73% | +$1.14M | ﹤0.01% | 1631 |
|
|
2024
Q3 | $1.82M | Sell |
40,357
-315,229
| -89% | -$14.2M | ﹤0.01% | 1944 |
|
|
2024
Q2 | $12.3M | Buy |
355,586
+283,768
| +395% | +$9.83M | ﹤0.01% | 575 |
|
|
2024
Q1 | $2.08M | Sell |
71,818
-37,865
| -35% | -$1.1M | ﹤0.01% | 1776 |
|
|
2023
Q4 | $2.52M | Buy |
109,683
+52,438
| +92% | +$1.2M | ﹤0.01% | 1708 |
|
|
2023
Q3 | $955K | Buy |
57,245
+41,281
| +259% | +$689K | ﹤0.01% | 2621 |
|
|
2023
Q2 | $441K | Sell |
15,964
-108,120
| -87% | -$2.99M | ﹤0.01% | 3778 |
|
|
2023
Q1 | $2.85M | Buy |
124,084
+57,053
| +85% | +$1.31M | ﹤0.01% | 1585 |
|
|
2022
Q4 | $731K | Sell |
67,031
-79,457
| -54% | -$867K | ﹤0.01% | 2707 |
|
|
2022
Q3 | $1.24M | Buy |
146,488
+81,328
| +125% | +$686K | ﹤0.01% | 2258 |
|
|
2022
Q2 | $516K | Buy |
65,160
+14,406
| +28% | +$114K | ﹤0.01% | 3302 |
|
|
2022
Q1 | $1.2M | Sell |
50,754
-245,659
| -83% | -$5.82M | ﹤0.01% | 2584 |
|
|
2021
Q4 | $10.1M | Buy |
296,413
+29,030
| +11% | +$993K | ﹤0.01% | 769 |
|
|
2021
Q3 | $4.74M | Buy |
267,383
+246,050
| +1,153% | +$4.36M | ﹤0.01% | 1202 |
|
|
2021
Q2 | $957K | Sell |
21,333
-12,801
| -38% | -$574K | ﹤0.01% | 3037 |
|
|
2021
Q1 | $884K | Buy |
34,134
+13,781
| +68% | +$357K | ﹤0.01% | 3147 |
|
|
2020
Q4 | $410K | Buy |
20,353
+9,133
| +81% | +$184K | ﹤0.01% | 3607 |
|
|
2020
Q3 | $219K | Buy |
+11,220
| New | +$219K | ﹤0.01% | 3828 |
|
|
2019
Q2 | – | Sell |
-47,788
| Closed | -$601K | – | 4911 |
|
|
2019
Q1 | $601K | Buy |
47,788
+32,580
| +214% | +$410K | ﹤0.01% | 1700 |
|
|
2018
Q4 | $102K | Buy |
+15,208
| New | +$102K | ﹤0.01% | 3180 |
|